Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 4.19% and Operating profit at -1.93% over the last 5 years
2
Flat results in Mar 25
3
With ROE of 10.04%, it has a very attractive valuation with a 2.09 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 24,081 Million (Large Cap)
21.00
NA
4.57%
-0.32
8.33%
2.12
Revenue and Profits:
Net Sales:
1,581 Million
(Quarterly Results - Sep 2025)
Net Profit:
305 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.25%
0%
-3.25%
6 Months
-9.47%
0%
-9.47%
1 Year
-12.98%
0%
-12.98%
2 Years
-28.99%
0%
-28.99%
3 Years
-19.67%
0%
-19.67%
4 Years
-59.56%
0%
-59.56%
5 Years
-62.54%
0%
-62.54%
Hualan Biological Engineering, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.19%
EBIT Growth (5y)
-1.93%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.21
Sales to Capital Employed (avg)
0.38
Tax Ratio
13.41%
Dividend Payout Ratio
33.56%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.57%
ROE (avg)
14.71%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
2.09
EV to EBIT
15.80
EV to EBITDA
12.98
EV to Capital Employed
2.84
EV to Sales
4.52
PEG Ratio
NA
Dividend Yield
1.25%
ROCE (Latest)
18.00%
ROE (Latest)
10.04%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
1,580.70
930.60
69.86%
Operating Profit (PBDIT) excl Other Income
355.90
257.50
38.21%
Interest
0.90
2.80
-67.86%
Exceptional Items
4.80
7.10
-32.39%
Consolidate Net Profit
305.00
198.90
53.34%
Operating Profit Margin (Excl OI)
225.20%
201.40%
2.38%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 69.86% vs 8.31% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 53.34% vs -38.57% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
4,360.50
5,319.20
-18.02%
Operating Profit (PBDIT) excl Other Income
1,451.00
2,084.20
-30.38%
Interest
13.40
13.50
-0.74%
Exceptional Items
32.90
60.50
-45.62%
Consolidate Net Profit
1,155.50
1,761.70
-34.41%
Operating Profit Margin (Excl OI)
270.30%
340.40%
-7.01%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -18.02% vs 18.24% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -34.41% vs 41.21% in Dec 2023
About Hualan Biological Engineering, Inc. 
Hualan Biological Engineering, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






